TD Asset Management Inc Has $7.67 Million Holdings in Axsome Therapeutics, Inc. $AXSM

TD Asset Management Inc lessened its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 5.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 41,972 shares of the company’s stock after selling 2,220 shares during the quarter. TD Asset Management Inc owned about 0.08% of Axsome Therapeutics worth $7,666,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in shares of Axsome Therapeutics by 6.0% during the 3rd quarter. Vanguard Group Inc. now owns 4,180,646 shares of the company’s stock worth $507,739,000 after purchasing an additional 235,626 shares during the period. Wellington Management Group LLP lifted its stake in shares of Axsome Therapeutics by 84.1% in the third quarter. Wellington Management Group LLP now owns 1,334,560 shares of the company’s stock valued at $162,082,000 after buying an additional 609,516 shares during the period. Geode Capital Management LLC grew its position in Axsome Therapeutics by 1.3% during the fourth quarter. Geode Capital Management LLC now owns 1,010,249 shares of the company’s stock worth $184,544,000 after buying an additional 12,549 shares in the last quarter. Invesco Ltd. raised its holdings in Axsome Therapeutics by 73.3% in the 3rd quarter. Invesco Ltd. now owns 990,557 shares of the company’s stock valued at $120,303,000 after acquiring an additional 419,008 shares in the last quarter. Finally, State Street Corp lifted its position in shares of Axsome Therapeutics by 5.8% in the 2nd quarter. State Street Corp now owns 958,503 shares of the company’s stock worth $100,058,000 after acquiring an additional 52,483 shares during the period. Institutional investors and hedge funds own 81.49% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on AXSM shares. Wells Fargo & Company lifted their price objective on Axsome Therapeutics from $225.00 to $255.00 and gave the stock an “overweight” rating in a report on Tuesday, May 5th. Jefferies Financial Group lifted their target price on shares of Axsome Therapeutics from $245.00 to $275.00 and gave the company a “buy” rating in a research report on Monday, May 4th. Robert W. Baird upped their target price on shares of Axsome Therapeutics from $241.00 to $246.00 and gave the company an “outperform” rating in a research note on Tuesday, May 5th. Deutsche Bank Aktiengesellschaft set a $280.00 price target on shares of Axsome Therapeutics in a research note on Tuesday, May 5th. Finally, Guggenheim upped their price objective on Axsome Therapeutics from $245.00 to $260.00 and gave the company a “buy” rating in a research note on Monday, May 4th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $251.26.

Axsome Therapeutics Trading Up 4.5%

AXSM stock opened at $245.64 on Wednesday. The company has a quick ratio of 1.32, a current ratio of 1.39 and a debt-to-equity ratio of 2.27. Axsome Therapeutics, Inc. has a twelve month low of $96.09 and a twelve month high of $246.41. The company has a market cap of $12.64 billion, a P/E ratio of -65.86 and a beta of 0.61. The business has a fifty day moving average of $205.86 and a 200-day moving average of $179.97.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings data on Monday, May 4th. The company reported ($1.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.41). Axsome Therapeutics had a negative return on equity of 267.16% and a negative net margin of 26.59%.The firm had revenue of $191.20 million during the quarter, compared to analyst estimates of $191.10 million. The company’s revenue for the quarter was up 57.4% compared to the same quarter last year. As a group, equities research analysts expect that Axsome Therapeutics, Inc. will post -2.24 EPS for the current year.

Insiders Place Their Bets

In other Axsome Therapeutics news, CFO Nick Pizzie sold 33,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 9th. The shares were sold at an average price of $240.09, for a total transaction of $7,922,970.00. Following the sale, the chief financial officer directly owned 42,867 shares in the company, valued at approximately $10,291,938.03. This trade represents a 43.50% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Mark L. Jacobson sold 4,517 shares of the stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $227.94, for a total transaction of $1,029,604.98. Following the transaction, the chief operating officer owned 4,517 shares of the company’s stock, valued at approximately $1,029,604.98. This represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 112,457 shares of company stock worth $26,364,328 in the last three months. 20.60% of the stock is owned by corporate insiders.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.